Bone marrow microenvironment and myelodysplastic syndrome
- VernacularTitle:骨髓微环境与骨髓增生异常综合征
- Author:
Yang-yang LYU
1
;
Zhi-gang ZHAO
Author Information
1. Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China
- Publication Type:Journal Article
- Keywords:
bone marrow;
myelodysplastic syndromes;
microenvironment;
review
- From:
Tianjin Medical Journal
2018;46(8):842-846
- CountryChina
- Language:Chinese
-
Abstract:
The myelodysplastic syndrome (MDS) is a heterogeneous group of clonal disorders originating from
hematopoietic stem cells (HSC), characterized by unilineage or multilineage dysplasia of myeloid cells, ineffective
hematopoiesis, peripheral blood cytopenias and high risk of transform into acute myeloid leukemia (AML). The pathogenesis,
hematopoietic function change and prognosis of MDS are closely related to the bone marrow microenvironment. Bone marrow
microenvironment is a complex network system, among them, stromal cells including abnormal morphology and function of
mesenchymal stem cells, impaired osteoblast differentiation, increased number of vascular endothelial cells, and decreased
number of monocytes/macrophages can promote the pathogenesis of MDS. The abnormal expression of cytokines such as
tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1 (SDF-1) are
also closely related to the pathogenesis of MDS. Low expression of genes such as Dicer1, high expression of AURKA, and low
expression of SPINT2 all contribute to the pathogenesis of MDS. Aberrant activation of Wnt/β-catenin signaling pathways,
abnormal PI3K/AKT and Hh signaling pathways are also involved in the pathogenesis and progression of MDS. The study of
the interaction between MDS and bone marrow microenvironment will further elucidate the pathogenesis, progress and
prognosis of the disease, and will contribute to the development of targeted therapy. This review provides the research
progress of bone marrow microenvironment stromal cells, cytokines, genes, and signaling pathway abnormalities in MDS.
